Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Receivables (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Change in Receivables for 13 consecutive years, with $42.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 247.71% year-over-year to $42.0 million, compared with a TTM value of $56.8 million through Dec 2025, up 173.2%, and an annual FY2025 reading of $56.8 million, up 173.2% over the prior year.
  • Change in Receivables was $42.0 million for Q4 2025 at Tandem Diabetes Care, up from $1.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $42.0 million in Q4 2025 and bottomed at -$22.8 million in Q1 2023.
  • Average Change in Receivables over 5 years is $5.6 million, with a median of $7.1 million recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 201.17% in 2021, then skyrocketed 247.71% in 2025.
  • Year by year, Change in Receivables stood at $24.2 million in 2021, then crashed by 87.47% to $3.0 million in 2022, then skyrocketed by 84.41% to $5.6 million in 2023, then surged by 115.96% to $12.1 million in 2024, then surged by 247.71% to $42.0 million in 2025.
  • Business Quant data shows Change in Receivables for TNDM at $42.0 million in Q4 2025, $1.3 million in Q3 2025, and $2.7 million in Q2 2025.